Trials / Recruiting
RecruitingNCT07330050
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Phase II Clinical Trial Evaluating Whole Agonist-Stimulated T (WAST) Cells in Combination With Docetaxel as a Second-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) Resistant to PD-1 Inhibitors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This prospective Phase II study aims to evaluate the preliminary efficacy and safety of WAST cells combined with docetaxel as second-line therapy in patients with advanced NSCLC resistant to PD-1 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Whole Agonist-Stimulated T (WAST) cells injection | WAST cells (≥4.0 × 10⁹ cells), intravenous infusion, d14, Q3W for 4 cycles. |
| DRUG | Docetaxel | 75 mg/m², intravenous infusion, day 1, Q3W. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
- First posted
- 2026-01-09
- Last updated
- 2026-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07330050. Inclusion in this directory is not an endorsement.